Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical GroupCGPHF 86 Return-on-Tangible-Asset is 0.66% as of Dec. 2025, which is 93% below its 10-year median of 9.43. GuruFocus rates CGPHF with a GF Scoreâ„¢ of 86/100. The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 62.36% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Grand Pharmaceutical Group's annualizedNet Income for the quarter that ended in Dec. 2025 was $18.47 Mil. Grand Pharmaceutical Group's average total tangible assets for the quarter that ended in Dec. 2025 was $2,796.28 Mil. Therefore, Grand Pharmaceutical Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 0.66%.
The historical rank and industry rank for Grand Pharmaceutical Group's Return-on-Tangible-Asset or its related term are showing as below:
CGPHF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.69 Med: 9.43 Max: 14
Current: 5.74
During the past 13 years, Grand Pharmaceutical Group's highest Return-on-Tangible-Asset was 14.00%. The lowest was 4.69%. And the median was 9.43%.
CGPHF's Return-on-Tangible-Asset is ranked better than 62.36% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs CGPHF: 5.74
Grand Pharmaceutical Group (OTCPK:CGPHF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companyÂ’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companyÂ’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Grand Pharmaceutical Group Return-on-Tangible-Asset Related Terms
Grand Pharmaceutical Group Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group Return-on-Tangible-Asset Chart
CGPHF vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 0.66% mean?
Grand Pharmaceutical Group (CGPHF) has a Return-on-Tangible-Asset of 0.66% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Grand Pharmaceutical Group and its competitors. This is 93% below median its historical median of 9.43. Over the past decade, Grand Pharmaceutical Group's Return-on-Tangible-Asset has ranged from 4.69 to 14.00. According to the industry distribution chart, Grand Pharmaceutical Group ranks #379 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 37.6%.
Is Grand Pharmaceutical Group's Return-on-Tangible-Asset too high?
Grand Pharmaceutical Group's current Return-on-Tangible-Asset of 0.66% is 93% below median its 10-year median of 9.43. Over the past 10 years, this metric has ranged from a low of 4.69 to a high of 14.00. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Grand Pharmaceutical Group's value of 0.66% is 79.1% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #379 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Scoreâ„¢ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #379 out of 1007 companies for Return-on-Tangible-Asset. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Grand Pharmaceutical Group's value of 0.66% is 79.1% below this benchmark. Historically, Grand Pharmaceutical Group's own Return-on-Tangible-Asset has ranged from 4.69 to 14.00 over the past decade. While the company's 10-year median is 9.43 vs. the industry median of 3.16, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Return-on-Tangible-Asset of 0.66% is 79.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Return-on-Tangible-Asset is 0.66%, which is 93% below median its own 10-year median of 9.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Return-on-Tangible-Asset of 0.66%. The current Return-on-Tangible-Asset is 0.66%, which is 93% below median its 10-year median of 9.43 and 79.1% below the Drug Manufacturers industry median of 3.16. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Return-on-Tangible-Asset is 0.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 
